XCEL-UMC-BETA(Syntax for Science)(XCEL-UMC-BETA(Syntax for Science))

概要

基本信息

药物类型

间充质干细胞疗法

别名-

靶点-

作用机制

干细胞替代物

治疗领域

神经系统疾病其他疾病

在研适应症-

非在研适应症

脊髓损伤创伤性脊髓损伤

原研机构

Syntax for Science, S.L

在研机构-

非在研机构

Recerca Clinica SLSyntax for Science, S.L

最高研发阶段无进展临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 XCEL-UMC-BETA(Syntax for Science) 相关的临床试验

NCT04390139 / Completed临床1/2期IIT

A Prospective, Double-blind, Randomized, Parallel, Placebo-controlled Pilot Clinical Trial for the Evaluation of the Efficacy and Safety of Two Doses of WJ-MSC in Patients With Acute Respiratory Distress Syndrome Secondary to Infection by COVID-19

Randomized, double-blind, parallel, two-arms clinical trial to assess the efficacy and safety of 2 infusions of Wharton-Jelly mesenchymal stromal cells (day 1 and day 3, endovenously at 1E6cells/Kg per dose) in patients with moderate acute respiratory distress syndrome (ARDS) secondary to SARS-CoV-2 infection. Follow-up will be established on days 3, 5, 7, 14, 21, and 28. Long term follow-up will be performed at 3, 6 and 12 months.

开始日期2020-05-13

申办/合作机构

Banc de Sang I Teixits

NCT03003364 / Completed临床1/2期IIT

A Phase I/IIa, Randomized, Double-blind, Single-dose, Placebo Controlled, Two-way Crossover Clinical Trial to Assess the Safety and to Obtain Efficacy Data in Intrathecal Administration of Expanded Wharton's Jelly Mesenchymal Stem Cells in Chronic Traumatic Spinal Cord Injury

This is a phase I/IIa, randomized, double-blind, two-arms, two-dose administration, placebo controlled, two-way crossover clinical trial in which 10 patients from 18 to 65 years of age affected with chronic traumatic spinal cord will enter the study with the objective to assess the safety and to obtain efficacy data in intrathecal administration of expanded Wharton's jelly mesenchymal stem cells.

开始日期2016-12-27

申办/合作机构

Banc de Sang I Teixits

[+2]

100 项与 XCEL-UMC-BETA(Syntax for Science) 相关的临床结果

登录后查看更多信息

100 项与 XCEL-UMC-BETA(Syntax for Science) 相关的转化医学

登录后查看更多信息

100 项与 XCEL-UMC-BETA(Syntax for Science) 相关的专利（医药）

登录后查看更多信息

100 项与 XCEL-UMC-BETA(Syntax for Science) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脊髓损伤	临床2期	西班牙	Syntax for Science, S.L	2016-12-27
脊髓损伤	临床2期	西班牙	Recerca Clinica SL	2016-12-27
创伤性脊髓损伤	临床2期	西班牙	Syntax for Science, S.L	2016-12-27
创伤性脊髓损伤	临床2期	西班牙	Recerca Clinica SL	2016-12-27